✦ LIBER ✦

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

✍ Scribed by Mohamad A. Hussein; Mansoor Saleh; Farhad Ravandi; James Mason; Robert M. Rifkin; Ralph Ellison

Book ID: 108672630
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 89 KB
Volume: 125
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2004.04941.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Tanespimycin and bortezomib combination

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

✍ Paul G. Richardson; Asher A. Chanan-Khan; Sagar Lonial; Amrita Y. Krishnan; Mich 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

Phase II and pharmacokinetic study of th

Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma

✍ Hirokazu Murakami; Kazuyuki Shimizu; Morio Sawamura; Kenshi Suzuki; Isamu Sugiur 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 207 KB

Efficacy and safety of melphalan, arseni

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study

✍ James R. Berenson; Ralph Boccia; David Siegel; Marek Bozdech; Alberto Bessudo; E 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 573 KB

Pharmacokinetics of arsenic species in J

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

✍ Shinya Fujisawa; Ryuzo Ohno; Kazuyuki Shigeno; Naohi Sahara; Satoki Nakamura; Ke 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 225 KB

A phase 2 study of two doses of bortezom

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

✍ S. Jagannath; B. Barlogie; J. Berenson; D. Siegel; D. Irwin; P. G. Richardson; R 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB